Size | Price | |
---|---|---|
10mg | ||
25mg | ||
50mg | ||
100mg | ||
250mg |
Purity: ≥98%
Calyculin A is a novel, potent, selective and cell-permeable inhibitor of protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) with IC50s of 0.5 to 1 nM. Calyculin A is a natural product and a marine toxin isolated from Disodermia calyx. Calyculin A does not have significant effect against PP2B, PP2C, and PP4.2 Through its effects on PP1 and PP2A, calyculin A has been shown to either promote or inhibit cancer cell growth in tumor cell lines and animal models.
Cell Assay |
Cytotoxicity assay [2]
Cell Types: human osteosarcoma MG63 cells Tested Concentrations: 0, 1, 2, 5, CalycuLin A (1-10 nM; 24 hrs (hours)) induces cytotoxicity in MG63 cells in a dosed manner [2]. 10 nM Incubation Duration: 24 hrs (hours) Experimental Results: Treatment with 0.1 nM for 24 hrs (hours) had minimal effect on MG63 cell survival. Cell rounding and shrinkage were evident in cultures treated with 5 nM for 24 hrs (hours). Cell viability levels treated with 10 nM were 27% of control cultures. |
---|---|
References |
[1]. Ishihara H, et al. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem Biophys Res Commun. 1989 Mar 31;159(3):871-7.
[2]. Hiroaki Tanaka,et al. Calyculin A induces apoptosis and stimulates phosphorylation of p65NF-kappaB in human osteoblastic osteosarcoma MG63 cells. Int J Oncol. 2007 Aug;31(2):389-96. |
Molecular Formula |
C50H81N4O15P
|
---|---|
Molecular Weight |
1009.16974
|
CAS # |
101932-71-2
|
SMILES |
O[C@@H]([C@H]([C@@H](N(C)C)COC)O)C(NCC[C@@H](C1=NC(/C=C/C[C@@H]([C@@H](C)[C@H](O)C2)O[C@@]32C(C)(C)[C@@H](OP(O)(O)=O)[C@@H]([C@@H](OC)C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C(C)/C(C)=C/C=C/C(C)=C\C#N)O3)=CO1)C)=O
|
InChi Key |
FKAWLXNLHHIHLA-YCBIHMBMSA-N
|
InChi Code |
InChI=1S/C50H81N4O15P/c1-29(20-22-51)16-14-17-30(2)32(4)24-33(5)42(57)35(7)38(55)25-41(65-13)45-46(69-70(61,62)63)49(8,9)50(68-45)26-39(56)34(6)40(67-50)19-15-18-36-27-66-48(53-36)31(3)21-23-52-47(60)44(59)43(58)37(28-64-12)54(10)11/h14-18,20,24,27,31,33-35,37-46,55-59H,19,21,23,25-26,28H2,1-13H3,(H,52,60)(H2,61,62,63)/b16-14+,18-15+,29-20-,30-17+,32-24+/t31-,33+,34-,35-,37-,38-,39+,40-,41-,42+,43-,44-,45+,46-,50+/m0/s1
|
Chemical Name |
(2R,3R,5R,7S,8S,9R)-2-((1S,3S,4S,5R,6R,7E,9E,11E,13Z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraen-1-yl)-7-((E)-3-(2-((S)-4-((2S,3S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanamido)butan-2-yl)oxazol-4-yl)allyl)-9-hydroxy-4,4,8-trimethyl-1,6-dioxaspiro[4.5]decan-3-yl dihydrogen phosphate
|
Synonyms |
(-)-Calyculin A; Calyculin A; Hemicalyculin A;
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.9909 mL | 4.9546 mL | 9.9091 mL | |
5 mM | 0.1982 mL | 0.9909 mL | 1.9818 mL | |
10 mM | 0.0991 mL | 0.4955 mL | 0.9909 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.